This is the current release of the guideline.

Asthma

Evaluation
Management
Treatment

Allergy and Immunology
Family Practice
Internal Medicine

Health Care Providers
Physicians

To provide physicians and other health professionals with a practical guide for attaining optimal asthma control

Patients with asthma

Evaluation/Assessment

1. Assessment of asthma control including frequency of symptoms; frequency of rescue bronchodilator; frequency of night/morning symptoms; activity, work, and school limitations; pulmonary function tests
2. Periodic assessments of asthma including psychosocial status, adherence/compliance, medication's side effects, asthma triggers, and reviewing of asthma action plan

Management/Treatment

1. Maintaining or stepping-down therapy (in well-controlled asthma)
2. Stepping-up therapy (in not well-controlled asthma)
3. Pharmacotherapy including
   • Short-acting beta-agonist as needed
   • Low-dose inhaled corticosteroids (ICSs), leukotriene modifiers, theophylline, cromolyn, or nedocromil
   • Low-dose/medium-dose ICSs plus inhaled long-acting beta-agonist (LABA) or medium-dose ICSs; low-dose/medium-dose ICSs plus either leukotriene modifier or theophylline
   • High-dose ICSs and LABA plus systemic corticosteroids if needed (consider monoclonal anti-IgE)

• Values of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV₁)
• Quality of life
• Emergency department use and hospitalizations for asthma

Searches of Electronic Databases

The development of these practice parameters included a MEDLINE search using the key words "asthma control" with selection of articles on the basis of expert opinion.

Not stated

Weighting According to a Rating Scheme (Scheme Given)

Ia Evidence from meta-analysis of randomized controlled trials

Ib Evidence from at least one randomized controlled trial

IIa Evidence from at least one controlled study without randomization

IIb Evidence from at least one other type of quasi-experimental study

III Evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies

IV Evidence from expert committee reports, opinions or clinical experiences of respected authorities, or both

Systematic Review

Published clinical studies or reports were rated by category of evidence and used to establish the strength of the clinical recommendations.

Expert Consensus

In 1991, the National Heart, Lung, and Blood Institute (NHLBI) published its first set of guidelines for the diagnosis and management of asthma. This publication introduced the concept of classification of asthma by asthma severity (mild, moderate, and severe) and linked asthma severity to a stepwise guide to pharmacotherapy of asthma. "Attaining optimal asthma control: a practice parameter" builds on the foundation of the NHLBI asthma report and extends the concept of guideline-driven asthma management.

Asthma management driven by assessment of asthma control emphasizes and operationalizes the goals of asthma therapy, as originally listed in the NHLBI Expert Panel Report. Assessment and targets of asthma control also builds on the step-up and step-down guideline, as recommended in the NHLBI report. Perhaps more importantly, control-driven asthma guidelines encompass the principles of chronic disease management, including periodic assessment, goal (outcome) orientation, and individualization of therapy.

1. Directly based on category I evidence
2. Directly based on category II evidence or extrapolated recommendation from category I evidence
3. Directly based on category III evidence or extrapolated recommendation from category I or II evidence
4. Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence

   NR Not rated

A formal cost analysis was not performed and published cost analyses were not reviewed.

Peer Review

Not stated

Guideline recommendations are presented in the form of summary statements. After each statement is a letter that indicates the strength of the recommendation. Grades of recommendations (A-D, Not rated) and levels of evidence (Ia, Ib, IIa, IIb, III, IV) are defined at the end of the "Major Recommendations" field.

Summary Statements

Asthma Severity and Asthma Control

1. Asthma symptoms do not always correlate with asthma severity. There are limitations to classifying asthma severity in patients already being treated. (B)
2. Management based on asthma control encompasses the principles of chronic disease management, including periodic assessment, goal (outcome) orientation, and individualization of therapy. (B)

Assessment of Asthma Control

3. Asthma control can be expected to change over time. Asthma control should be assessed at every clinical encounter for asthma, and management decisions should be based on the level of asthma control. (B)
4. Asthma control is based on asthma symptoms, sleep disturbance, use of rescue medication, limitations of daily activity, patient and physician overall assessment, and lung function. (A)
5. Asthma should be considered well controlled if (1) asthma symptoms are twice a week or less; (2) rescue bronchodilator medication is used twice a week or less; (3) there is no nocturnal or early morning awaking; (4) there are no limitations of work, school, or exercise; (5) the patient and physician consider their asthma well controlled; and (6) the patient's peak expiratory flow (PEF) or forced expiratory volume in one second (FEV₁) is normal or his or her personal best. (B)
6. Complete or total control of asthma can be defined as (1) no asthma symptoms; (2) no rescue bronchodilator use; (3) no nighttime or early morning awakening; (4) no limitations on exercise, work, or school; (5) complete control of asthma by patient and physician assessment; and (6) normal or personal best PEF or FEV₁. (A)
7. In addition to the assessment of asthma control, there are several important activities that should be accomplished during the periodic visit for asthma, including assessment of psychosocial status, assessment of adherence-compliance, assessment of medication use and side effects, assessment of asthma triggers, review of written asthma action plan (as appropriate), and confirmation of asthma diagnosis. (B)

Step Care Based on Asthma Control

8. A patient's asthma control for a specific clinical encounter should be determined as well controlled or not well controlled. (B)
9. A more detailed assessment of asthma should be conducted, especially for patients whose asthma is not well controlled. (B)
10. The step care of asthma should be based on asthma control. (A)

Physician's Role in Attaining Asthma Control

11. Asthma management driven by level of asthma control demands a close partnership between physician and patient. (B)

Definitions:

Category of Evidence

Ia Evidence from meta-analysis of randomized controlled trials

Ib Evidence from at least one randomized controlled trial

IIa Evidence from at least one controlled study without randomization

IIb Evidence from at least one other type of quasi-experimental study

III Evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies

IV Evidence from expert committee reports, opinions or clinical experiences of respected authorities, or both

Strength of Recommendation

1. Directly based on category I evidence
2. Directly based on category II evidence or extrapolated recommendation from category I evidence
3. Directly based on category III evidence or extrapolated recommendation from category I or II evidence
4. Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence

   NR Not rated

"Algorithm for Attaining Optimal Asthma Control" is provided in the original guideline document.

The type of supporting evidence is identified and graded for each summary statement (see "Major Recommendations" field).

Improved asthma control

Adverse effects of pharmacotherapy

This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official American Academy of Allergy, Asthma, and Immunology (AAAAI) or American College of Allergy, Asthma, and Immunology (ACAAI) interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma, and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.

An implementation strategy was not provided.

Getting Better
Living with Illness

Effectiveness
Patient-centeredness

This practice parameter builds on the foundation of the National Heart. Lung, and Blood Institute (NHLBI) asthma report, National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health Publication No. 91-3642. 1991.

2005 Nov

American Academy of Allergy, Asthma and Immunology - Medical Specialty Society
American College of Allergy, Asthma and Immunology - Medical Specialty Society
Joint Council of Allergy, Asthma and Immunology - Medical Specialty Society

These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology.

Funded by the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology (ACAAI), and the Joint Council of Allergy, Asthma and Immunology (JCAAI).

Joint Task Force on Practice Parameters

Chief Editors: James T. Li MD, PhD, Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn; John Oppenheimer, MD, Department of Internal Medicine, New Jersey Medical School, Pulmonary and Allergy Associates, Morristown, NJ; I. Leonard Bernstein, MD, Department of Medicine and Environmental Health, University of Cincinnati College of Medicine, Cincinnati, Ohio; Richard A. Nicklas, MD, Clinical Professor of Medicine, George Washington Medical Center, Washington, DC

Joint Task Reviewers: David A. Khan, MD, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Tex; Joann Blessing-Moore, MD, Departments of Medicine and Pediatrics, Stanford University Medical Center, Department of Immunology, Palo Alto, Calif; David M. Lang, MD, Allergy/Immunology Section, Division of Medicine, Director, Allergy and Immunology Fellowship Training Program, Cleveland Clinic Foundation, Cleveland, Ohio; Jay M. Portnoy, MD, Section of Allergy, Asthma & Immunology, The Children's Mercy Hospital, Professor of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Mo; Diane E. Schuller, MD, Department of Pediatrics, Pennsylvania State University,  Milton S. Hershey Medical College, Hershey, Pa; Sheldon L. Spector, MD, Department of Medicine, UCLA School of Medicine, Los Angeles, Calif; Stephen A. Tilles, MD, Department of Medicine, University of Washington School of Medicine, Redmond, Wash; Dana V. Wallace, MD, Nova Southeastern University, Davie, Fla

Reviewers: John Cohn, MD, Philadelphia, Pa; A. Gilbert, MD, Dallas, Tex; Andy Nish, MD, Gainesville, Ga; Bruce Prenner, MD, San Diego, Calif; David Stempel, MD, Bellevue, Wash; Steven Weinstein, MD, Huntington Beach, Calif; Brock Williams, MD

J. Li had consultant arrangements with Roche, Novartis, and Glaxo; has received grants from Astra Zeneca, Glaxo, and Schering; and has received honoraria from Merck, Astra Zeneca, and Glaxo.

I. Bernstein has stock in Glaxo.

J. Oppenheimer has consultant arrangements with Sepracor, Glaxo, Astra Zeneca, and Roche; has received grants from Sepracor, Glaxo, Astra Zeneca, Schering Sanofi, Boehringer Ingelheim, and Merck; and is on the speaker's bureau for Sepracor, Glaxo, Schering Sanofi, and Boehringer Ingelheim.

This parameter was edited by Dr Nicklas in his private capacity and not in his capacity as a medical officer with the Food and Drug Administration. No official support or endorsement by the Food and Drug Administration is intended or should be inferred.

This is the current release of the guideline.

None available

None available

This NGC summary was completed by ECRI on January 16, 2006. The information was verified by the guideline developer on February 21, 2006.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Joint Council of Allergy, Asthma, and Immunology for more information.